The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …

Immunotherapy using T cells genetically engineered to express a chimeric antigen receptor
(CAR) is rapidly emerging as a promising new treatment for haematological and non …

T cells engineered to express chimeric antigen receptors (CARs) with tumor specificity have
shown remarkable success in treating patients with hematologic malignancies and …

Regulatable CAR platforms could circumvent toxicities associated with CAR-T therapy, but
existing systems have shortcomings including leakiness and attenuated activity. Here, we …

Chimeric antigen receptor (CAR) T cell therapy has garnered significant excitement due to
its success for hematological malignancies in clinical studies leading to the US Food and …

Cellular immunotherapies represent a promising approach for the treatment of cancer.
Engineered adoptive cell therapies redirect and augment a leukocyte's inherent ability to …

T cells engineered to express chimeric antigen receptors (CARs) that are specific for tumour
antigens have led to high complete response rates in patients with haematologic …

Cell therapies have emerged as a promising therapeutic modality with the potential to treat
and even cure a diverse array of diseases. Cell therapies offer unique clinical and …

A major obstacle for chimeric antigen receptor (CAR) T cell therapy in solid tumors is the
lack of truly tumor-specific target antigens, which translates to the targeting of tumor …

Genetically engineered T cell immunotherapies have provided remarkable clinical success
to treat B cell acute lymphoblastic leukaemia by harnessing a patient's own T cells to kill …